Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors-MedSci.cn

Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

Denker, S; Bittner, A; Frick, M; Kase, J; Hoffmann, J; Trenker, C; Keller, U; Bogner, C; Huttmann, A; Duhrig, J; Janz, M; Mathas, S; Marks, R; Krohn, U; Bhattacharya, A; Na, IK; Gebauer, B; Savic, LJ; Hubner, N; Akalin, A; Eils, R; Bullinger, L; Schmitt, CA